 |
Brentuximab vedotin |
|---|---|
| Trade Name | Adcetris |
| Orphan Indication | Primary cutaneous CD30-positive T-cell lymphoproliferative disorders |
| USA Market Approval | USA |
| USA Designation Date | 2016-09-07 00:00:00 |
| Sponsor | Seattle Genetics, Inc.;21823 30th Drive Southeast;Bothell, Washington, 98021 |
